Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.

Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.

The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.